阿托伐他汀钙治疗血脂正常的短暂性脑缺血发作临床疗效观察

Clinical effect of atorvastatin calcium in the treatment of patients with transient ischemic attack but average blood lipid level

目的观察阿托伐他汀钙对血脂正常的短暂脑缺血发作患者血脂水平的影响及临床疗效。方法将79例血脂正常的短暂性脑缺血发作患者随机分为治疗组(40例)和对照组(39例),治疗组给予常规治疗外加服阿托伐他汀钙;对照组仅作常规治疗。检测治疗前后血脂水平,比较6个月内两组患者脑血管事件发生率。结果治疗组脑血管事件发生率(12.5%)低于对照组(30.8%)(P<0.05),治疗前两组血脂水平差异无统计学意义(P均>0.05),治疗后治疗组血清总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)较治疗前明显降低,高密度脂蛋白胆固醇(HDL-C)显著升高(P<0.01),而对照组治疗前后无显著变化(P>0.05),治疗后两组血脂水平比较差异有统计学意义(P均<0.01)。结论阿托伐他汀钙不仅有调控血脂水平的作用,而且对短暂性脑缺血发作的二期预防有显著疗效,可降低卒中发生率。

Objective To observe the effects of atorvastatin calcium on blood lipid level of patients with transient ischemic attack but average blood lipid level and its clinical efficacy. Methods Seventy-nine patients with transient ischemic attack but average blood lipid level were randomly assigned to treatment group （ n = 40） and control group （ n = 39）. Treatment group received atorvastatin calcium with conventional treatment for six months, the control group received only conventional treatment. The blood lipid levels before and after treatment in both groups were de- termined. The cerebral vascular incident rates were compared within six months between two groups. Results The cerebral vascular incident rates were 12.5% and 30. 8% for treatment group and control group respectively, there was significant difference between the two groups （ P 〈 0. 05 ）. Before treatment there was no significant difference in blood lipid levels between two groups （P all 〉 0.05 ）. In treatment group after treatment, the levels of blood cholesterol, tri- glyceride and low-density lipoprotein significantly decreased and high-density lipoprotein significantly increased （P 〈 0. 05）. In control group, there was no significant difference in blood lipid levels before and after treatment （ P 〉 O. 05） ,there was significant difference in blood lipid levels between two groups after treatment（P all 〈 0. 01 ）. Con- clusion Atorvastatin calcium can not only adjust blood lipids levels,but has remarkable effect for the secondary pre- vention of transient ischemic attack. It can reduce the incidence of stroke.